Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Petros PharmaceuticalsPTPI -6.06% 3-Year EPS without NRI Growth Rate is 76.10% as of Jun. 2026, which is 67% above its 10-year median of 45.70. The stock has 1 warning sign investors should review. Among 783 Drug Manufacturers companies, Petros Pharmaceuticals ranks better than 95.27% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 76.10% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 63.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 7 years, the highest 3-Year average EPS without NRI Growth Rate of Petros Pharmaceuticals was 76.10% per year. The lowest was 26.80% per year. And the median was 45.70% per year.
Petros Pharmaceuticals (OTCPK:PTPI) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Petros Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms
PTPI vs GRPS, KOAN, OWPC: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Petros Pharmaceuticals 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Petros Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.
Petros Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 76.10% mean?
Petros Pharmaceuticals (PTPI) has a 3-Year EPS without NRI Growth Rate of 76.10% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Petros Pharmaceuticals and its competitors. This is 67% above median its historical median of 45.70. Over the past decade, Petros Pharmaceuticals' 3-Year EPS without NRI Growth Rate has ranged from 26.80 to 76.10. According to the industry distribution chart, Petros Pharmaceuticals ranks #37 out of 783 companies in the Drug Manufacturers industry, placing it in the top 4.7%.
Is Petros Pharmaceuticals' 3-Year EPS without NRI Growth Rate too high?
Petros Pharmaceuticals' current 3-Year EPS without NRI Growth Rate of 76.10% is 67% above median its 10-year median of 45.70. Over the past 10 years, this metric has ranged from a low of 26.80 to a high of 76.10. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.80. Petros Pharmaceuticals' value of 76.10% is 676.5% above this industry median. Based on the distribution chart, Petros Pharmaceuticals ranks #37 out of 783 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Petros Pharmaceuticals' 3-Year EPS without NRI Growth Rate compare to GRPS and KOAN?
According to the Drug Manufacturers industry distribution chart, Petros Pharmaceuticals ranks #37 out of 783 companies for 3-Year EPS without NRI Growth Rate. This places Petros Pharmaceuticals in the top 5% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 9.80. Petros Pharmaceuticals' value of 76.10% is 676.5% above this benchmark. Historically, Petros Pharmaceuticals' own 3-Year EPS without NRI Growth Rate has ranged from 26.80 to 76.10 over the past decade. While the company's 10-year median is 45.70 vs. the industry median of 9.80, Petros Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.80, based on 783 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Petros Pharmaceuticals's current 3-Year EPS without NRI Growth Rate of 76.10% is 676.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Petros Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petros Pharmaceuticals's current 3-Year EPS without NRI Growth Rate is 76.10%, which is 67% above median its own 10-year median of 45.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current 3-Year EPS without NRI Growth Rate of 76.10%. The current 3-Year EPS without NRI Growth Rate is 76.10%, which is 67% above median its 10-year median of 45.70 and 676.5% above the Drug Manufacturers industry median of 9.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current 3-Year EPS without NRI Growth Rate is 76.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTPI has been successfully added to your 
